Eligo Bioscience

🚀 Join us in shaping the future of precision microbiome medicines 🚀 If you enjoyed our recent publication in Nature and are passionate about advancing innovative technology to the clinic, we have exciting opportunities for you! We are expanding our team and looking for talented individuals to join us in the following roles: 🔬 Senior Biochemist Scientist: Lead manufacturing and process development of first-in-class phage-derived genetic medicines. 🧬 Microbial Synthetic Biologist: Engineer non-model bacteria and phages. 💻 Bioinformatics Scientist: Multiomics analysis and computer assisted design of viral particles. 📋 Regulatory & Quality Manager: Lead our acne vulgaris program through clinical development. Explore these opportunities and apply here: https://eligo.bio/careers/

🧬 We are thrilled to announce the publication of our recent work in Nature Magazine, demonstrating for the first time that it is possible to genetically modify bacteria with nearly 100% efficiency directly in the gut of animals. 🧫 This leap forward provides scientists with a novel strategy to better understand how genes from our microbiome drive disease, and gives Eligo Bioscience a unique edge in the development of first-in-class gene editing therapies. Jesus Fernandez-Rodriguez, PhD, Eligo VP of Technology and a senior author of the study, highlights how "this achievement is the culmination of eight years of work by the team at Eligo and represents a paradigm shift in microbiome research to find novel therapeutic targets. We finally now have a tool to interrogate the role of specific bacterial genes in health and disease." "What Eligo has achieved shows that it’s now possible to make specific changes to the DNA of bacteria in the gut, similar to how scientists have been editing human genes to investigate or treat genetic disorders," said David Bikard, co-founder of Eligo Bioscience, Head of the Synthetic Biology Lab at the Institut Pasteur in Paris, and a senior author of the study. Congratulations to co-first authors Andreas Broedel and Loïc Charpenay , all the other authors (Matthieu Galtier, Fabien J. Fuche, Chloé Poquet, Rémi Terrasse, Marion Arraou, Gautier Prevot, Dalila Spadoni, Jan Havránek, Simone Pignotti, Antonina Krawczyk, PhD, Matthew Yarnall, Edith Hessel, Jesus Fernandez-Rodriguez, PhD, Xavier Duportet, David Bikard) and the entire Eligo team who have been innovating at the frontier of science to make in vivo genome editing of the microbiome a reality. This achievement wouldn't have been possible without the invaluable contributions from every team member, whose collective efforts drive our success. #TeamEffort -- Read the press release here: https://lnkd.in/eA-pQEkN Read the paper in Open Access here: https://lnkd.in/eRDjxeXa Making this work available in Open Access underscores our dedication to sharing knowledge with the broader scientific community. Our goal is to foster collaborative efforts in the gene editing and microbiome fields. We are eager to engage with fellow researchers and organizations to accelerate discoveries and expedite the development of therapies for patients. -- We are thankful for the unwavering support of our investors: Sanofi Ventures Khosla Ventures, Seventure Partners, and InnoBio Bpifrance Life Sciences Venture/Bpifrance.

🚨 Job Alert: Senior Biochemist Opportunity! 🚨 -- 🧬 Are you ready to work on a first-in-class modality at the cutting edge of gene-editing, viral particles, and microbiology? 🧑🔬 Aurélie MATHIEU, who is brilliantly leading our Microbiology & Early CMC team, is hiring a Senior Biochemist. This role offers the chance to contribute to groundbreaking advancements as we rapidly progress towards clinical trials. Join us and be a part of something extraordinary! Apply now! 🌟 #JobAlert #Hiring #Biochemist #Microbiology #GeneEditing #Biotech #CareerOpportunity #JoinOurTeam https://lnkd.in/edn6rnqz

Thank you David Wild for the conversation and this article!

🦠 Skin microbes play a pivotal role in health and disease modulation. What if we could alter disease trajectories by modifying how these microbes communicate with their host? 🧬 Eligo has spearheaded groundbreaking technologies for editing the genomes of skin commensal bacteria. Now, we're expanding our Host-Microbiome Interaction team, under the leadership of Igor Stzepourginski, to develop first-in-class genetic medicines capable of precisely shaping the genetic landscape of the skin microbiome. ✅ Seize this unique opportunity to be at the forefront of gene editing, microbiome research, and immunology with us! Join our mission today. https://lnkd.in/e7ksTivC

Exciting times at Eligo! Following our Series B announcement, we're gearing up to take the first-ever topical CRISPR therapy to the clinic. If you're eager to have a meaningful impact on the lives of millions of patients, we would love to hear from you. We are indeed on the lookout for passionate and driven individuals to join our Development, Finance, Synthetic Biology & Bioinformatics teams. https://eligo.bio/careers/

Our CEO, Xavier Duportet, was invited by stephane soumier on BSMART TV to discuss Eligo's journey and what lies ahead for us following our recent fundraising announcement. Thank you stephane soumier! #CRISPSR #Biotech #Frenchtech #Microbiome #GeneEditing https://lnkd.in/g472VgBG

🎉 News alert: We are thrilled to announce that we have just closed a $30 million financing round led by Sanofi Ventures, with the participation of Bpifrance (Innobio2), and our existing investors Khosla Ventures and Seventure Partners.  🧬 This funding will enable us to advance and test in the clinic our CRISPR-based medicine for the 90M+ patients suffering from moderate-to-severe acne vulgaris. It will also help us to further develop our proprietary platform to address other immuno-inflammatory diseases, cancers, and infectious diseases.  🚀 This is a defining moment for Eligo as this funding places us in a strong position to make a significant leap in treating diseases by editing the genetic makeup of the human microbiome. #CRISPR #SyntheticBiology #GeneEditing #Microbiome #Acnetreatment https://lnkd.in/ejTC-DXS

🚀 🧬 Stay tuned...